Back to results

Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Objective

To compare MK-2870 to TPC with respect to PFS per RECIST 1.1 as assessed by BICR in all participants. To compare MK-2870 plus pembrolizumab to TPC with respect to PFS per RECIST 1.1 as assessed by BICR in all participants.

Protocol #

MK-2870-010

Trial Phase:

Phase III

Principal Investigator:

Vachhani, Hetal

Cancer Type
  • Breast
Study Site
  • Virginia Commonwealth University

Has unresectable locally advanced or metastatic centrally-confirmed HR+/HER2- breast cancer
An individual of any sex/gender, from at least 18 years of age at the time of providing the informed consent

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Lindsey Gwaltney, MS, RN
    Phone: +1 804-628-2112
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: